Abstract
Cancer has been described as one of the major and leading causes of death worldwide. By the year 2030, it has been postulated that over 21.4 million new cases of cancer could be expected, 17 million cancer deaths yearly and a total of 75 million people will be living with cancer within five years of diagnosis. Chemotherapy is the main therapeutic intervention for treating people living with SCC. However, drug resistance has rendered it inefficient and ineffective in combating the disease even after combination chemotherapy. Many peptides and proteins have been investigated to possess biological activities that mark them as potential anti-cancer agents. Targeting peptides are conjugated with other functional peptides or nanoparticles to augment drug delivery both in vitro and in vivo assays. The current identification of tumor-homing peptides through phage display technology has opened a new strategy for targeted therapy in SCC diseases. Despite the advances in cancer nanomedicine, targeted approaches in the delivery of therapeutics for the treatment of squamous cell carcinoma related tumours have not been well established. In this review, current drugs employed in cancer nanomedicine are highlighted, possible rate limiting factors for the application of polymeric materials in cancer nanomedicine are elucidated and functionalized nano-constructs using receptor ligands and homing peptides as targeted moieties are discussed. The combinatorial strategy of attaching both homing peptides and receptor ligands as dual moieties on nano-cargos should further strengthen the advantages of each technology in cancer targeted therapy.
Keywords: Cancer, chemotherapy, homing peptides, nanoparticles, receptor ligands, squamous cell carcinoma.
Current Pharmaceutical Design
Title:Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Volume: 21 Issue: 22
Author(s): Adeyemi S. Adebowale, Yahya E. Choonara, Pradeep Kumar, Lisa C. du Toit and Viness Pillay
Affiliation:
Keywords: Cancer, chemotherapy, homing peptides, nanoparticles, receptor ligands, squamous cell carcinoma.
Abstract: Cancer has been described as one of the major and leading causes of death worldwide. By the year 2030, it has been postulated that over 21.4 million new cases of cancer could be expected, 17 million cancer deaths yearly and a total of 75 million people will be living with cancer within five years of diagnosis. Chemotherapy is the main therapeutic intervention for treating people living with SCC. However, drug resistance has rendered it inefficient and ineffective in combating the disease even after combination chemotherapy. Many peptides and proteins have been investigated to possess biological activities that mark them as potential anti-cancer agents. Targeting peptides are conjugated with other functional peptides or nanoparticles to augment drug delivery both in vitro and in vivo assays. The current identification of tumor-homing peptides through phage display technology has opened a new strategy for targeted therapy in SCC diseases. Despite the advances in cancer nanomedicine, targeted approaches in the delivery of therapeutics for the treatment of squamous cell carcinoma related tumours have not been well established. In this review, current drugs employed in cancer nanomedicine are highlighted, possible rate limiting factors for the application of polymeric materials in cancer nanomedicine are elucidated and functionalized nano-constructs using receptor ligands and homing peptides as targeted moieties are discussed. The combinatorial strategy of attaching both homing peptides and receptor ligands as dual moieties on nano-cargos should further strengthen the advantages of each technology in cancer targeted therapy.
Export Options
About this article
Cite this article as:
Adebowale S. Adeyemi, Choonara E. Yahya, Kumar Pradeep, du Toit C. Lisa and Pillay Viness, Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects, Current Pharmaceutical Design 2015; 21 (22) . https://dx.doi.org/10.2174/1381612821666150531165331
DOI https://dx.doi.org/10.2174/1381612821666150531165331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pseudogene PTENP1 Suppresses Gastric Cancer Progression by Modulating PTEN
Anti-Cancer Agents in Medicinal Chemistry Proteomics Studies in Oncology Towards Personalized Medicine in Public Health: Opportunities and Challenges for OMICS Research in Iran
Current Pharmacogenomics and Personalized Medicine The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Garlic (<i>Allium sativum</i> L.): Its Chemistry, Nutritional Composition, Toxicity, and Anticancer Properties
Current Topics in Medicinal Chemistry Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Current Drug Targets Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Studies of NVP-BEZ235 in Melanoma
Current Cancer Drug Targets Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry